Simplex Trading, LLC Immutep LTD Transaction History

Simplex Trading, LLC

$175 Billion
Q2 2025

A detailed history of Simplex Trading, LLC transactions in Immutep LTD stock. As of the latest transaction made, Simplex Trading, LLC holds 61 shares of IMMP stock, worth $103. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 51 19.61%

Holding current value

$103

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 05, 2025	BUY	$1.41 - $2.49 $14 - $24	10 Added 19.61%	61 $0
Q1 2025 May 12, 2025	SELL	$1.7 - $2.21 $17,426 - $22,654	-10,251 Reduced 99.5%	51 $0
Q4 2024 Feb 11, 2025	BUY	$1.82 - $2.36 $18,749 - $24,312	10,302 New	10,302 $22,000
Q2 2024 Jul 25, 2024	SELL	$1.87 - $3.23 $16,046 - $27,716	-8,581 Reduced 26.76%	23,490 $47,000
Q1 2024 Apr 25, 2024	BUY	$2.11 - $2.89 $7,777 - $10,652	3,686 Added 12.99%	32,071 $74,000
Q4 2023 Feb 02, 2024	BUY	$1.76 - $2.49 $49,957 - $70,678	28,385 New	28,385 $68,000
Q2 2023 Aug 04, 2023	BUY	$1.54 - $2.62 $779 - $1,325	506 New	506 $1,000
Q4 2022 Feb 02, 2023	SELL	$1.6 - $2.53 $13,382 - $21,160	-8,364 Reduced 76.89%	2,514 $4,000
Q3 2022 Nov 04, 2022	SELL	$1.56 - $2.29 $21,077 - $30,940	-13,511 Reduced 55.4%	10,878 $16,000
Q2 2022 Aug 03, 2022	SELL	$1.96 - $3.09 $3,041 - $4,795	-1,552 Reduced 5.98%	24,389 $49,000
Q1 2022 May 02, 2022	SELL	$2.3 - $3.61 $63,178 - $99,163	-27,469 Reduced 51.43%	25,941 $71,000
Q4 2021 Feb 23, 2022	BUY	$3.09 - $4.81 $158,319 - $246,445	51,236 Added 2356.76%	53,410 $175,000
Q2 2021 Aug 12, 2021	BUY	$3.02 - $5.21 $6,565 - $11,326	2,174 New	2,174 $8,000

Others Institutions Holding IMMP

# of Institutions

Shares Held

1.98M

Call Options Held

12.1K

Put Options Held

36.3K

View Full List

About IMMUTEP Ltd

Ticker IMMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,624,000
Market Cap $147M
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as...

More about IMMP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account

Simplex Trading, LLC Immutep LTD Transaction History